Home / Market News / $INSM
benzinga Corporate Catalyst Impact 55/100 ● negative

Barclays Maintains Overweight on Insmed, Lowers Price Target to $207

Sep 30, 2026, 3:37 PM UTC · Primary ticker $INSM

Barclays analyst Eliana Merle has reiterated an 'Overweight' rating on Insmed but reduced the price target from $237 to $207. This indicates a continued positive outlook on the company's long-term prospects, albeit with a slightly tempered near-term valuation expectation.

Barclays analyst Eliana Merle maintained an 'Overweight' rating on Insmed, signaling continued confidence in the company's fundamentals and future growth. However, the price target was lowered from $237 to $207, which suggests a recalibration of valuation expectations, possibly due to market conditions, competitive landscape, or updated financial models. This news primarily affects Insmed (INSM) directly, as it provides an updated analyst perspective that could influence investor sentiment. In the short term, the lowered price target might exert some downward pressure on the stock, while the maintained 'Overweight' rating could provide long-term support. For traders, the key risk is potential short-term volatility due to the price target adjustment, while the opportunity lies in assessing whether the market overreacts to the target change versus the maintained positive rating.

$INSM negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.